Park et al. examined PD-L1 expression in patient tumour samples with tissue microarray (TMA) analysis carried out with three different antibody clones [40]: ≥1% of PD-L1 expression was observed in 20%, 17.6% and 16.3% of undifferentiated pleomorphic sarcomas with PD-L1 22C3, SP263 and SP142 antibodies, respectively. This evidence concerns the gene CD274 and sarcoma.